ClinicalTrials.gg
Active, not recruitingNCT07181590BLAST-OFFUpdated Oct 21, 2026

BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF

An interventional study of Pulsed Field Ablation in Paroxysmal AF, Atrial Arrhythmia and Atrial Fibrillation, sponsored by Abbott Medical Devices. Active, not recruiting at 22 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Atrial Fibrillation by Abbott — 3 open to participants now, 9 under way, none of them phase 3. Atrial Fibrillation · Abbott.

Enrollment
11th of 43
300 · median 200
Started
2025
with 1 other
No phase
39 of 70
3 open now
Registered
67th of 70
by date

Among the 70 studies in Atrial Fibrillation by Abbott, this one is the 11th largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2025, is one of 39 with no phase, and was the 67th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 70 studies in Atrial Fibrillation by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Atrial Fibrillation by Abbott, or all of them as a file.
02

Study summary

This study is designed to obtain real-world clinical evidence on the safety and effectiveness of the Volt PFA System in various use cases, with a sub study designed to address additional clinical evidence needs in electrophysiology.

03

Conditions studied

  • Paroxysmal AF
  • Atrial Arrhythmia
  • Atrial Fibrillation
  • Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
  • Pulsed Field Ablation
  • Persistent Field Ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented symptomatic PAF or PersAF. Documentation requirements are as follows:

    Paroxysmal:

    • Physician's note indicating recurrent self-terminating AF AND
    • One electrocardiographically documented PAF episode within 12 months prior to enrollment.

    Persistent: Continuous AF sustained beyond 7 days and less than 1 year that is documented by

    • Physician's note, AND either
    • 24-hour Holter within 360 days prior to enrollment, showing continuous AF, OR
    • Two (from any form of rhythm monitoring) showing continuous AF:

      • That are taken at least 7 days apart but less than 12 months apart
      • If electrograms are more than 12 months apart, there must be one or more Sinus Rhythm recordings in between or within 12 months prior to consent/enrollment
      • The most recent electrocardiogram must be within 180 days of enrollment.

    NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of AF from another ECG device.

  2. Plans to undergo a de novo ablation procedure with the Volt PFA Catheter due to symptomatic PAF or PersAF and is , intolerant, or to at least one Class I-IV AAD medication
  3. At least 18 years of age
  4. Able and willing to comply with all trial requirements including pre-procedure, post- procedure, and follow-up testing and requirements
  5. Informed of the nature of the trial, agreed to its provisions, and has provided written as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical trial site.

Exclusion criteria

Exclusion Criteria

  1. Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures in the preceding 90 days
  2. Known presence of cardiac thrombus
  3. Known \< 35% as assessed with echocardiography within 360 days of index procedure
  4. (NYHA) class III or IV heart failure
  5. Pregnant, nursing, or planning to become pregnant during the clinical investigation follow-up period
  6. Patients who have had a ventriculotomy or atriotomy within the preceding 30 days of procedure
  7. Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 90 days
  8. Unstable angina
  9. Stroke or (transient ischemic attack) within the last 90 days
  10. Heart disease in which corrective surgery is anticipated within 180 days after procedure
  11. History of blood clotting or bleeding abnormalities including thrombocytosis, thrombocytopenia, bleeding diathesis, or suspected anti-coagulant state
  12. to long term anti-thromboembolic therapy
  13. Patient unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
  14. Previous left atrial surgical or left atrial catheter ablation procedure (including LAA closure device)
  15. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2).
  16. Previous tricuspid or mitral valve replacement or repair
  17. Patients with prosthetic valves
  18. Patients with a myxoma
  19. Patients with an interatrial baffle or patch as the transseptal puncture could persist and produce an iatrogenic atrial shunt
  20. Stent, constriction, or stenosis in a pulmonary vein
  21. Rheumatic heart disease
  22. Hypertrophic cardiomyopathy
  23. Diagnosed with amyloidosis or atrial amyloidosis
  24. Active systemic infection
  25. Renal failure requiring dialysis
  26. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or ) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
  27. Presence of an implanted LAA closure device
  28. Patient is currently participating in another clinical study that may confound the results of this of this post market evaluation; for example, enrolled in another study with an active treatment arm
  29. Unlikely to survive the protocol follow up period of 12 months
  30. Presence of other medical, anatomic, comorbid, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
  31. Individuals without legal authority
  32. Individuals unable to read or write
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Other
    Volt PFA Catheter Sensor Enabled (SE)

    Patients diagnosed with drug refractory, symptomatic, recurrent, paroxysmal and persistent atrial fibrillation that will undergo a de novo ablation procedure with the Volt PFA Catheter.

    Device: Pulsed Field Ablation

Interventions

  • DevicePulsed Field Ablation

    Pulsed Field Ablation using the Volt PFA System

06

What researchers measure

Primary outcomes

  1. Rate of subjects experiencing a device and/or procedure-related serious adverse event with onset within 7 days of any ablation procedure that uses Volt AF

    Serious adverse events are defined as: * Atrio-esophageal fistula * Cardiac tamponade/perforation * Death * Heart block * Myocardial infarction * Pericarditis3 * Phrenic nerve injury resulting in permanent diaphragmatic paralysis * Pulmonary Edema * Pulmonary vein stenosis1 * Stroke * Thromboembolism * Transient ischemic attack * Vagal nerve injury/gastroparesis * Major vascular access complications4 / major bleeding events5 * Device related cardiovascular and/or pulmonary adverse event that prolongs hospitalization for more than 48 hours (excluding hospitalization solely for arrhythmia recurrence or non-urgent cardioversion)

    Time frame: 7 days

  2. Long-term Effectiveness will be the proportion of subjects with freedom from documented AF/AFL/AT recurrence through 12-months.

    Other situations in which subjects will be considered effectiveness endpoint failures include: * Cardioversion (electrical or pharmaceutical) for the treatment of AF/AFL/AT following the blanking period. * A second repeat procedure for ablation of AF recurrence within the 90-day blanking period * Any repeat ablation procedure in the left atrium (LA) for AF/AFL/AT following the 90-day blanking period * Any use of a new class I or III AAD for AF/AFL/AT after the 90-day blanking period * Any use of a class I or III AAD for AF/AFL/AT at a dose higher than the historical maximum dose for the subject after the blanking period.

    Time frame: During procedure

  3. Acute procedural effectiveness is defined as confirmation of entrance block in all targeted pulmonary veins

    A secondary measure of confirmation to include any one of the following (the same method must be used for all pulmonary veins) : * A minimum 20-minute wait following initial confirmation of entrance block with a second confirmation of entrance block following the 20-minute wait; or * Exit block pacing maneuvers ; or * Isoproterenol or adenosine challenge

    Time frame: During procedure

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 21 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Aug 2027 → Sep 2027 and completion Aug 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 18, 2025
StartActual
Dec 11, 2025
Primary completionEst.
Sep 2027was Aug 2027
CompletionEst.
Sep 2027was Aug 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 21, 2026
Primary completion
Aug 2027→Sep 2027
Oct 21, 2026
Study completion
Aug 2027→Sep 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Active, not recruiting
    Primary completion Aug 2027→Sep 2027
    Study completion Aug 2027→Sep 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07181590
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Dec 11, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Sarah C Kammer
study director · Abbott Medical Devices

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion